Literature DB >> 22160648

Analysis of dose-volume parameters predicting radiation pneumonitis in patients with esophageal cancer treated with 3D-conformal radiation therapy or IMRT.

Gaurav Kumar1, Sheh Rawat, Abhishek Puri, Manoj Kumar Sharma, Pranav Chadha, Anand Giri Babu, Girigesh Yadav.   

Abstract

PURPOSE: Multimodality therapy for esophageal cancer can cause various kinds of treatment-related sequelae, especially pulmonary toxicities. This prospective study aims to investigate the clinical and dosimetric parameters predicting lung injury in patients undergoing radiation therapy for esophageal cancer.
METHODS: Forty-five esophageal cancer patients were prospectively analyzed. The pulmonary toxicities (or sequelae) were evaluated by comparing chest X-ray films, pulmonary function tests and symptoms caused by pulmonary damage before and after treatment. All patients were treated with either three-dimensional radiotherapy (3DCRT) or with intensity-modulated radiotherapy (IMRT). The planning dose volume histogram was used to compute the lung volumes receiving more than 5, 10, 20 and 30 Gy (V5, V10, V20, V30) and mean lung dose.
RESULTS: V20 was larger in the IMRT group than in the 3DCRT group (p = 0.002). V20 (>15%) and V30 (>20%) resulted in a statistically significant increase in the occurrence of chronic pneumonitis (p = 0.03) and acute pneumonitis (p = 0.007), respectively.
CONCLUSIONS: The study signifies that a larger volume of lung receives lower doses because of multiple beam arrangement and a smaller volume of lung receives higher doses because of better dose conformity in IMRT plans. Acute pneumonitis correlates more with V30 values, whereas chronic pneumonitis was predominantly seen in patients with higher V20 values.

Entities:  

Mesh:

Year:  2011        PMID: 22160648     DOI: 10.1007/s11604-011-0002-2

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  36 in total

Review 1.  Intensity modulated radiation therapy: a clinical review.

Authors:  C Nutting; D P Dearnaley; S Webb
Journal:  Br J Radiol       Date:  2000-05       Impact factor: 3.039

Review 2.  The relevance of transforming growth factor beta 1 in pulmonary injury after radiation therapy.

Authors:  M S Anscher; F M Kong; R L Jirtle
Journal:  Lung Cancer       Date:  1998-02       Impact factor: 5.705

3.  Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method.

Authors:  G J Kutcher; C Burman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-06       Impact factor: 7.038

4.  Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus.

Authors:  J F Bosset; M Gignoux; J P Triboulet; E Tiret; G Mantion; D Elias; P Lozach; J C Ollier; J J Pavy; M Mercier; T Sahmoud
Journal:  N Engl J Med       Date:  1997-07-17       Impact factor: 91.245

5.  A quantitative treatment planning study evaluating the potential of dose escalation in conformal radiotherapy of the oesophagus.

Authors:  J L Bedford; L Viviers; Z Guzel; P J Childs; S Webb; D M Tait
Journal:  Radiother Oncol       Date:  2000-11       Impact factor: 6.280

6.  A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy.

Authors:  C M Nutting; J L Bedford; V P Cosgrove; D M Tait; D P Dearnaley; S Webb
Journal:  Radiother Oncol       Date:  2001-11       Impact factor: 6.280

7.  Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.

Authors:  Susan L Tucker; H Helen Liu; Shulian Wang; Xiong Wei; Zhongxing Liao; Ritsuko Komaki; James D Cox; Radhe Mohan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-11       Impact factor: 7.038

8.  Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery.

Authors:  Shu-lian Wang; Zhongxing Liao; Ara A Vaporciyan; Susan L Tucker; Helen Liu; Xiong Wei; Stephen Swisher; Jaffer A Ajani; James D Cox; Ritsuko Komaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-19       Impact factor: 7.038

9.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Authors:  T N Walsh; N Noonan; D Hollywood; A Kelly; N Keeling; T P Hennessy
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

10.  Evaluation of an objective plan-evaluation model in the three dimensional treatment of nonsmall cell lung cancer.

Authors:  M V Graham; N L Jain; M G Kahn; R E Drzymala; J A Purdy
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-01-15       Impact factor: 7.038

View more
  13 in total

1.  Associated factors of radiation pneumonitis induced by precise radiotherapy in 186 elderly patients with esophageal cancer.

Authors:  Zhen Cui; Ye Tian; Bin He; Hongwei Li; Duojie Li; Jingjing Liu; Hanfei Cai; Jianjun Lou; Hao Jiang; Xueming Shen; Kaigui Peng
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT.

Authors:  Stefan Münch; Sylvia Aichmeier; Alexander Hapfelmeier; Marciana-Nona Duma; Markus Oechsner; Marcus Feith; Stephanie E Combs; Daniel Habermehl
Journal:  Strahlenther Onkol       Date:  2016-07-14       Impact factor: 3.621

3.  Chemoradiotherapy for localized extranodal natural killer/T-cell lymphoma, nasal type, using a shrinking-field radiation strategy: multi-institutional experience.

Authors:  Yukiko Hattori; Taro Murai; Hiromitsu Iwata; Kaoru Uchiyama; Mikio Mimura; Eriko Kato; Rumi Murata; Yuta Shibamoto
Journal:  Jpn J Radiol       Date:  2016-02-06       Impact factor: 2.374

4.  Radiation pneumonitis in lung cancer treated with volumetric modulated arc therapy.

Authors:  Kan Wu; Xiao Xu; Xiadong Li; Jiahao Wang; Lucheng Zhu; Xueqin Chen; Bing Wang; Minna Zhang; Bing Xia; Shenglin Ma
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

5.  Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis.

Authors:  Hirokazu Makishima; Hitoshi Ishikawa; Toshiyuki Terunuma; Takayuki Hashimoto; Koichi Yamanashi; Takao Sekiguchi; Masashi Mizumoto; Toshiyuki Okumura; Takeji Sakae; Hideyuki Sakurai
Journal:  J Radiat Res       Date:  2015-03-09       Impact factor: 2.724

6.  DVH- and NTCP-based dosimetric comparison of different longitudinal margins for VMAT-IMRT of esophageal cancer.

Authors:  S Münch; M Oechsner; S E Combs; D Habermehl
Journal:  Radiat Oncol       Date:  2017-08-15       Impact factor: 3.481

7.  Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity.

Authors:  Matthias Felix Haefner; Kristin Lang; Vivek Verma; Stefan Alexander Koerber; Lorenz Uhlmann; Juergen Debus; Florian Sterzing
Journal:  Radiat Oncol       Date:  2017-08-15       Impact factor: 3.481

8.  Dosimetric comparison between proton beam therapy and photon radiation therapy for locally advanced esophageal squamous cell carcinoma.

Authors:  Yasuhiro Hirano; Masakatsu Onozawa; Hidehiro Hojo; Atsushi Motegi; Sadatomo Zenda; Kenji Hotta; Shunsuke Moriya; Hidenobu Tachibana; Naoki Nakamura; Takashi Kojima; Tetsuo Akimoto
Journal:  Radiat Oncol       Date:  2018-02-09       Impact factor: 3.481

9.  Radiation Pneumonitis after Intensity-Modulated Radiotherapy for Esophageal Cancer: Institutional Data and a Systematic Review.

Authors:  J J Tonison; S G Fischer; M Viehrig; S Welz; S Boeke; K Zwirner; B Klumpp; L H Braun; D Zips; C Gani
Journal:  Sci Rep       Date:  2019-02-19       Impact factor: 4.379

10.  Improving target coverage and organ-at-risk sparing in intensity-modulated radiotherapy for cervical oesophageal cancer using a simple optimisation method.

Authors:  Jia-Yang Lu; Michael Lok-Man Cheung; Bao-Tian Huang; Li-Li Wu; Wen-Jia Xie; Zhi-Jian Chen; De-Rui Li; Liang-Xi Xie
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.